New Cambridge Facility

Stem Cell Sciences plc
18 December 2006


18 December 2006
                     
                      Stem Cell Sciences Opens New Cambridge
                         Stem Cell Production Facility
                        ("Stem Cell Sciences" or "SCS")


Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on
the commercialisation of stem cells and stem cell technologies in research and
novel cell-based therapies, is pleased to announce that it has opened its new
automated stem cell production facility at the Babraham Research Campus in
Cambridge.

SCS' new facility will enable the Company to grow and supply its novel stem cell
based drug screens and assays for the world pharmaceutical industry using state
of the art robotic cell culture equipment, including the CompacT SelecT TM.
Combined with the company's range of stem cell lines, cell culture media and
sophisticated stem cell engineering tools, it now means SCS will be able to
supply the right quantity as well as quality of "cells in wells" needed for
advanced pharmaceutical research and development.

The company cell lines now include embryonic stem cells, neural stem cells that
can produce neurons, astrocytes and oligodendrocytes, and hMADS cells (fat
derived stem cells) that can produce adipocyte (fat) and osteoblast (bone)
cells.

Commenting on the opening of the new facility, SCS' Chairman, Dr Michael Dexter,
said:

"The opening of this facility is another step along the way to bringing stem
cells from the research bench to industry. Our investment at the Babraham
Research Campus gives SCS the capability to supply our stem cell based products
to the pharmaceutical industry in reproducible and cost effective ways, and is
an exciting step forward in the company's continuing development."

The new facility was formally opened on December 15th by Dr Mary Archer, Chair
of the East of England Stem Cell Network Steering Group and Chair of Cambridge
University Hospitals NHS Foundation Trust, who said:

"One of the bottlenecks in drug development is the time it takes to screen
candidate drugs for efficacy. The use of stem cell-derived cell lines for
screening promises much greater speed and efficiency than current methods, as
well as a reduced need for animal testing in pharmaceutical research and
development. I am delighted to see SCS introduce this new facility at Babraham."

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc
Hugh Ilyine, Vice President and Chief Operating Officer            0131 662 9829
Sue Furber, Director of Finance & Company Secretary

Weber Shandwick | Square Mile
Louise Robson                                                      020 7067 0700
James White

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,
established in Melbourne, Australia in 1994, providing products in the
burgeoning stem cell research and drug discovery markets, in addition to the
targeted development of cell-based therapies for neurodegenerative disease and
injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics. SCS
principal focus is in neurological disease. Revenues in the neurotech market,
including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110
billion (Neurotech Insights, Volume 2/3 April 30 2006).

SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(R) provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, part of
Millipore Corporation.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies' goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchenne Muscular Dystrophy in 2007-8.

For further information on the company please visit:
www.stemcellsciences.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange